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Nanoparticles are useful tools in oncology because of their capacity to passively accumulate in tumors 
in particular via the enhanced permeability and retention (EPR) effect. However, the importance and 
reliability of this effect remains controversial and quite often unpredictable. In this preclinical study, 
we used optical imaging to detect the accumulation of three types of fluorescent nanoparticles in eight 
different subcutaneous and orthotopic tumor models, and dynamic contrast-enhanced and vessel 
size index Magnetic Resonance Imaging (MRI) to measure the functional parameters of these tumors. 
The results demonstrate that the permeability and blood volume fraction determined by MRI are 
useful parameters for predicting the capacity of a tumor to accumulate nanoparticles. Translated to a 
clinical situation, this strategy could help anticipate the EPR effect of a particular tumor and thus its 
accessibility to nanomedicines.
Low-molecular-weight targeted anticancer drugs administered intravenously are usually homogeneously dis-
tributed in most tissues but are expected to eventually perform their (specific) function in cancer cells only. 
Depending on the importance and quality of this specific therapeutic activity, these drugs often provide insuffi-
cient therapeutic benefits and cause severe systemic toxicity. In such cases, it is expected that their entrapment 
in a nanoparticle (NP) will reduce their accumulation in healthy tissues while improving it in tumors via the 
so-called “enhanced permeability and retention (EPR) effect1,2”. Indeed, molecules less than 40–45 kDa can leak 
out of the tumor vascular bed by diffusion, depending on the difference in concentration between the therapeutic 
solution and tumor. They are also rapidly cleared as they are evacuated by the lymph and blood circulation. By 
contrast, larger molecules and NPs (up to 500 nm in size) have greater difficulties extravasating from the vascular 
bed. They benefit from the augmented permeability of tumor blood vessels to leak out of the vascular bed more 
efficiently than in normal tissues under a convection flow, which can be represented by the difference in pressure 
between the therapeutic solution and tumor. Large molecules are then captured in the tumor’s interstitial space. 
The quantitative importance of the EPR effect is thus related to the tumor biology (i.e., systolic blood pressure 
that pushes blood into the tumor tissue, blood and lymphatic vessel architecture and functions, interstitial fluid 
and extracellular matrix composition and pressure3–5, and the presence of tumor-associated cells and necrotic 
areas6), as well as to the physico-chemical properties of the NP’s (i.e., stealth, circulation times, size, electrostatic 
charge, shape, and density7–11). The EPR effect is expected to increase the NP’s therapeutic index while reducing 
its toxicity. However, the number of clinical applications derived from this concept and number of nanovectors 
approved for human use remains limited12–14.
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Altogether the intensity of the EPR effect remains extremely variable and unpredictable, and methods to 
estimate it in a given tumor to be treated are lacking. Thus far, predictive mathematical models are not practically 
applicable because too many parameters are measureless, ending up in an equation containing “black boxes6”.
We previously demonstrated that the combination of an iron-based steady-state vessel size index magnetic 
resonance imaging (VSI-MRI) approach using ultrasmall superparamagnetic iron oxide (USPIO) and a gadolin-
ium (Gd)-based dynamic contrast-enhanced MRI (DCE-MRI) approach using Dotarem® (Gd-DOTA) can be 
used to characterize the tumor microvasculature structure and permeability15–17. The present study investigated 
whether these clinically relevant measures could be used to anticipate how a given tumor can accept an NP, in a 
condition where there is no a priori knowledge of the physico-chemical properties of this NP.
The VSI- or DCE-MRI parameters were measured in eight different subcutaneous and orthotopic tumor mod-
els in mice. Next, optical imaging was used to evaluate if 5-nm or 50-nm large fluorescent NPs accumulate in 
the same tumors. Finally we evaluated whether the fluorescent signal could have been anticipated regarding the 
different MRI parameters taken separately or in combination. We demonstrate that it is possible to predict the 
capture of the fluorescent NPs in a given tumor based on two MRI parameters: the permeability and tumor blood 
volume fraction (BVf). This could help anticipate the capacity of a particular tumor to be “EPR sensitive”.
Results
Determination of the functional properties of the tumors using MRI. A total of thirty-five nude 
mice were engrafted with six different tumor cell lines, either with subcutaneous (SC) or orthotopic tumors (in 
the mammary fat pad with breast tumor cells or in the brain with glioblastoma cells). The chosen cell lines were 
of different origins and tumor stages (i.e., IGROV1 (human ovarian carcinoma cells), HT29 (human tumor cells, 
known to produce well-differentiated adenocarcinomas, comparable to colonic primary carcinoma (grade I in 
mice), TS/a-pc (spontaneous and highly metastatic murine adenocarcinoma derived from ductal cells of the 
mammary gland), U87MG (human glioblastoma grade IV), HUH-7 (well-differentiated hepatocellular human 
carcinoma cells), and HEK293(ß3) (transformed normal human embryonic kidney cells).
The anatomical view observed using a T2-weighted MRI sequence (Fig. 1) showed that HUH-7 tumors 
were heterogeneous, with large dark bloody areas. By contrast, the other tumor models were more homogenous 
throughout the entire tumor volume although small variations between adjacent nodules within the same tumor 
could be observed (as IGROV1 and U87MG examples).
Using a single MRI session (Fig. 2), it is possible to measure the tumor vessel’s permeability using Gd-DOTA 
(Dotarem®) and to measure the vessel size index (VSI) and tumor blood volume fraction (BVf) after the 
Figure 1. Anatomical views of the different tumor models. Six different tumor cell lines (HUH-7, 
HEK293(β 3), IGROV1, U87MG, HT29 and TS/a-pc) were subcutaneously and/or orthotopically engrafted 
into mice. Anatomical coronal views of these tumor-bearing mice were obtained using a T2-weighted MRI 
sequence.
Figure 2. Diagram of the imaging experimental protocol. MRI anatomical view is obtained with a T2-
weighted MRI sequence. LNC: lipid nanocapsule; P904: ultra small particle iron oxide (USPIO); EPI Diff: 
diffusion-weighted, spin-echo, single shot; MGESE: combined multi gradient-echo and spin-echo conventional 
MRI; EPI GESE: combined gradient-echo and spin-echo, single shot, EPI.
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administration of ultra small superparamagnetic iron oxide (USPIO). The data obtained after the injection of 
Gd-DOTA permitted distinguishing among four types of tumors with variable levels in vessel permeability (Fig. 3 
and Table 1). The HUH-7 tumors had a low permeability, with a low Gd signal after 2.5 minutes that decreased 
after 10 minutes. The TS/a-pc tumor vessels had heterogeneous permeability, for both subcutaneous and ortho-
topic tumors, as observed in HEK293(ß3) tumors. The strong Gd signal on the edge of the tumor suggested 
that there was an elevated permeability in the periphery of the tumor mass, whereas the rest of the tumor was 
impermeable. Tumors, such as U87MG or HT29, had an elevated permeability at their periphery 2.5 minutes 
after Dotarem® injection; thereafter, the Gd diffused rapidly toward the interior of the tumor. Interestingly, the 
orthotopic U87MG tumors exhibited a fairly homogeneous contrast enhancement. Finally, IGROV1 tumors were 
very permeable, and a strong signal was observed in large domains of the tumor, with Gd still diffusing 15 minutes 
after the injection (Fig. 3).
The intravenous injection of USPIOs allowed the investigation of tumor blood vessels parameters (Supp. 
Fig. 1). Both the “vessel diameter” and “blood volume fraction” measures were calculated from the VSI-MRI 
sequences. The MRI sequences were performed 20 seconds after the USPIO injection. In this time frame, USPIOs 
do not extravasate from the blood flow. The HUH-7 and HEK293(ß3) tumors were characterized by a small 
number (~18 vessels/0.573 mm2) of “standard size” blood vessels (~12 μ m in diameter) (Table 2). Others, such 
as U87MG and HT29 had an elevated number (> 30 vessels/0.573 mm2) of “standard size” blood vessels while 
IGROV1 tumors were vascularized by a small number of larger blood vessels. TS/a-pc tumors presented very 
different configurations depending on their implantation site: numerous “standard size” vessels in SC tumors, 
or a smaller number of large-diameter vessels (~16 μ m in diameter) when engrafted in the mammary fat pad. 
This trend was reversed when U87MG cells grew subcutaneously or orthotopically in the brain, suggesting that 
the physiological constraints in the organ of tumor development (i.e., brain and mammary fat pad) impacted 
greatly on the organization of the neo-vasculature and thus on the EPR effect. We also evaluated the number of 
blood vessels and mean vessel diameter after anti-CD31 immunohistochemistry (IHC) staining of tumor sections 
(Supp. Fig. 2). High correlations were obtained when IHC and MRI results were compared (p < 0.001), thus vali-
dating the MRI measurements (Table 2).
Passive accumulation of fluorescent nanoparticles. Fluorescent DID-containing 50-nm large lipidic 
nanocapsules (LNCs) were intravenously injected in the mice previously evaluated by MRI. These nanocap-
sules were distributed in the body with a blood half-life of 6.28 hours and a preferential hepatic elimination, as 
described in Basile et al.18 and summarized in the Supplementary Fig. 3A.
LNC accumulation was visualized using 2D-FRI (Fig. 4) and semi-quantified on isolated organs (Supp. Fig. 4), 
as well as on whole-body images to calculate the tumor/skin ratio. These analyses were performed 24 hours after 
LNC injection; at this time point, the amount of LNCs in the tumor is representative of their kinetic of accumula-
tion. The fluorescent signal of LNCs in tumors varied depending on the tumor model (Fig. 4 and Supp. Fig. 4B). 
Based on our experience of fluorescence in our imaging systems, an “EPR-negative” status was attributed to tum-
ors that presented a tumor/skin ratio inferior to 1.5, corresponding to fluorescence intensity less than 5,000 pho-
tons/pixel/50 ms for this batch of fluorescent LNCs and for these experimental conditions. Thus, tumors such as 
IGROV1, HT29, TS/a-pc and U87MG, with elevated fluorescence intensities and tumor/skin ratios greater than 
2, were considered “EPR-positive” tumors. By contrast, HUH-7 tumors and HEK293(ß3) were barely fluorescent 
and were considered as “EPR-negative” tissues (Fig. 4 and Supp. Fig. 4B). This confirmed our former results with 
HEK293(ß3), establishing also that the levels of LNCs in the tumors and in different organs were similar when 
measured by fluorescence or SPECT using dual-labeled DiD-99mTc-LNC19.
Figure 3. Evaluation of the permeability of the different tumors. Mice were imaged using a T1 MRI sequence 
immediately before (t = 0) and during the first 15 minutes after intravenous injection of Dotarem®. The 
hypersignal represents Dotarem®. Grayscale: 0–12,000.
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Prediction of LNC accumulation using the MRI measurements. We firstly tried to correlate each of 
the four parameters (tumor permeability, water diffusion coefficient, vessel diameter (VSI) or blood volume frac-
tion (BVf)) with the fluorescent signal (Table 1). Taken separately, none of these parameters directly correlated 
with the fluorescence intensity (Supp. Fig. 5).
We next examined whether the different MRI parameters could be combined in a linear regression to establish 
a correlation with fluorescence as follows:
= + × + × + × + × − ∈fluorescence intercept A AUC B Dti C dia D BVf
A correlation with the fluorescence intensity was possible only when using the permeability and vessel diam-
eter parameters together (Supp. Fig. 6). However, although each parameter had a significant impact on the equa-
tion with a p value < 0.2, the total R2 value of 0.264 was not satisfying and confirmed the poor correlation between 
fluorescence and the different MRI parameters.
Using another approach based on a “classification scheme”, we observed that combining “permeability” and 
“BVf ” measures could perfectly predict whether a given tumor was accessible by the 50-nm large LNCs (Fig. 5). 
Indeed, “EPR-negative” tumors could be characterized by their permeability less than 350,000 (AUC) and BVf 
less than 1.7%. Using these two limits, the “EPR-negative” group (n = 6/35) and “EPR-positive” group (n = 29/35) 
were satisfyingly defined with a p < 0.0001. This finding indicated that tumors with a low permeability index and 











# mean (RLU/pixel/50 ms) AUC μm2/s μm %
Subcutaneous
HUH-7
1 689 98,522 998 12.41 2.17
2 1,211 135,335 1,156 12.77 2.04
3 1,580 139,081 1,219 14.55 3.16
HEK293(β3)
1 4,659 420,034 827 14.48 1.28
2 4,941 381,695 1,232 14.34 1.02
3 4,790 269,158 879 10.54 1.25
IGROV1
1 9,682 795,062 1,537 14.12 2.44
2 12,505 519,448 1,495 13.05 2.86
3 16,574 752,720 1,092 17.24 1.83
4 10,288 569,030 1,356 15.86 2.81
HT29
1 13,953 590,555 1,623 13.27 2.19
2 11,062 361,986 1,762 14.47 2.22
3 17,997 316,137 1,413 14.11 2.09
4 6,252 350,655 1,216 12.69 1.66
5 10,573 609,850 1,345 16.70 2.73
TS/a-pc
1 23,076 820,437 1,073 14.06 3.14
2 13,094 622,315 948 12.16 2.42
3 9,761 302,853 965 11.94 2.41
U87MG
1 12,935 365,001 1,150 11.47 1.79
2 14,224 779,970 1,209 13.55 3.21
3 8,943 521,711 1,142 13.51 2.14
Orthotopic
TS/a-pc
1 8,589 677,228 882 13.43 2.34
2 10,311 677,525 1,292 15.67 2.67
3 9,897 838,269 1,602 17.17 3.10
4 19,681 447,632 1,479 18.14 3.68
5 21,012 352,881 1,133 17.00 3.68
6 21,471 452,775 1,539 16.60 2.68
U87MG
1 10,151 677,864 798 13.19 6.17
2 7,573 305,940 817 12.40 6.16
3 8,891 414,801 783 16.60 8.40
4 11,986 505,689 806 12.40 6.16
5 15,298 430,359 880 13.91 7.92
6 12,594 552,622 906 13.11 7.89
7 12,197 720,627 884 12.98 6.15
8 13,530 467,415 856 10.89 5.82
Table 1.  MRI and fluorescence data obtained for each mouse.
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Confirmation of the tumor accumulation variability using two other types of nanoparticles. 
To confirm the differences in the ability of tumors to accumulate LNCs, two other types of nanoparticles were 
evaluated : lipidic nanoemulsions (LNEs) and ultrasmall rigid platforms (USRPs) (See Supp. Fig. 3A–C).
LNEs are 50-nm DiD-loaded lipidic nanoparticles, with chemical properties close to those of LNCs, although 
their elasticity and surface coating are different. After intravenous injection, LNEs were distributed in the body 
with a hepatic elimination and a mean residence time of 8 hours in the blood20 (Supp. Fig. 3B).
LNEs were injected into a set of mice bearing the six types of subcutaneous tumors previously studied (n = 3/
group). The fluorescent signal was semi-quantified from whole-body images, and the tumor/skin ratios were 
calculated at different time points after intravenous injection of LNEs. In agreement with the data obtained with 
LNCs, the results showed that HUH-7 and HEK293(ß3) tumors exhibited tumor/skin ratios ranging from 1 to 
1.5, corresponding to “EPR-negative” tumors. By contrast, the four other tumor types (i.e., IGROV1, U87MG, 
Subcutaneous Orthotopic
HUH-7 HEK293(β3) IGROV1 U87MG HT29 TS/A-pc TS/A-pc U87MG
MRI vessel diameter 13.24 ± 1.14 13.12 ± 2.23 15.07 ± 1.85 12.84 ± 1.19 14.25 ± 1.54 12.72 ± 1.17 16.34 ± 1.63 13.19 ± 1.63
IHC vessel diameter 14.53 ± 0.27 11.71 ± 1.60 15.08 ± 1.98 10.40 ± 1.18 11.52 ± 0.86 8.93 ± 0.75 16.43 ± 3.87 9.96 ± 0.7
number of vessels 17.1 ± 6.6 17.9 ± 6.4 18.4 ± 6.4 31.4 ± 6.4 34.5 ± 8.6 40.3 ± 17.2 14.41 ± 6.92 46.56 ± 12.7
Table 2.  Evaluation of the vessel diameter and number by MRI and IHC in tumor sections. The number 
of vessels (number of vessels per 0.573 mm2) and their diameters (in μ m) were counted.These results were 
compared to vessel diameters (in μ m) initially determined by MRI. The results were expressed as the 
mean ± SD.
Figure 4. 2D-fluorescence images of subcutaneous (left panel) and orthotopic (right panel) tumor- 
bearing mice 24 hours after LNC intravenous injection (10 nmol of dye). (A) Images were acquired over a 
period of 100 ms and are presented in the same grayscale (1,700–30,000). The arrows indicate the tumors.  
(B) Corresponding tumor/skin ratios 24 hours after LNC injection. Note that tumor/skin ratio was not 
accessible for orthotopic U87MG brain tumors.
www.nature.com/scientificreports/
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HT29 and TS/a-pc) exhibited tumor/skin ratios greater than 1.5 as early as 3 hours after injection, reaching 2.5 at 
24 hours (Fig. 6). These tumors can be considered “EPR-positive”.
Next, the ability of fluorescent cyanine5.5-USRPs to accumulate in tumors was evaluated in mice bearing sub-
cutaneous HEK293(ß3) (n = 4), U87MG (n = 4), and TS/A-pc (n = 4). The USRPs are multimodal nanoparticles 
with a size less than 5 nanometers. They are composed of polysiloxane and gadolinium complexes covalently 
grafted to the inorganic matrix21. As indicated in Supp. Fig. 3C, the in vivo biodistribution of USRPs in healthy 
mice indicate that they have a blood half-life of 30 minutes and are eliminated exclusively by renal excretion22. 
As predicted, while the HEK293(ß3) tumors were presenting only background fluorescence similar to that of the 
surrounding healthy tissues (tumor/skin ratios ranging between 1.0 and 1.5), U87MG and TS/a-pc tumors were 
positively with tumor/skin ratios of 2.0 and 2.9, respectively. In these two last categories, the positive contrast was 
obtained as early as 1.5 hours after intravenous injection and is still detectable 24 hours later (Fig. 7).
Discussion
Although it is quite simple to evaluate the ADME (i.e., absorption, distribution, metabolism and excretion) of an 
NP, it is difficult to anticipate the physio-pathological fluctuations and inter-tumor variability that dictate how 
efficiently a given tumor in a given patient will be accessible or not to nanodrugs. We addressed this problem by 
following the distribution and passive EPR-mediated accumulation of intravenously injected 50-nm large fluo-
rescent lipid nanocapsules in eight different subcutaneous or orthotopic tumor models engrafted into mice. The 
quality of the EPR-based tumor targeting was then compared with various functional parameters obtained by 
dynamic contrast-enhanced MRI (DCE-MRI) and vessel size index MRI (VSI-MRI).
Despite well-known limitations i.e., the lack of anatomical information and poor penetration depth of light 
(requiring the use of near infrared dyes), the use of non-invasive fluorescence imaging has increased in the last 
decades23,24. This imaging tool is effective for monitoring the biodistribution of fluorescent NPs and visualizing 
inter-tumor variations of the passive accumulation in mouse-bearing tumor models. In this study, fluorescence 
imaging results clearly document the possible passive accumulation of two different types of 50-nm large NP (i.e., 
LNCs and LNEs) in different tumor types and allow for the differentiation of “EPR-negative” and “EPR-positive” 
Figure 5. Determination of the EPR status according to the “classification scheme”. AUC: area under the 
curve; BVf: blood volume fraction.
Figure 6. Passive accumulation of lipidic nanoemulsions (LNEs) in six different subcutaneous tumors 
after intravenous injection. The LNEs were intravenously injected (10 nmol of dye) into subcutaneous tumor-
bearing mice (n = 3/group). 2D-fluorescence imaging was performed before and 1.5 hours, 3 hours, 5 hours and 
24 hours after the injection of LNEs. Tumor and skin fluorescence signals were semi-quantified on whole-body 
images. The results are presented as the mean ± SD.
www.nature.com/scientificreports/
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tumors. These results also confirm the biodistribution and whole pharmacokinetic measurements that were pre-
viously obtained with a similar batch of fluorescent-only25,26 or dual-labeled (fluorescent and radioactive) LNCs19.
Interestingly, similar variations of the passive tumor accumulation were obtained after injection of the very 
small USRPs (< 5 nm in size). Maeda et al.2,13,27 described that the EPR effect apply to NPs and macromolecules 
with an apparent molecular size larger than 40 kDa and a long blood circulation time (> 6 hours). USRPs have 
a molecular size of 8.5 kDa and a blood half-life of 30 minutes, and thus, their passive accumulation cannot be 
formerly attributed to the EPR effect. However, USRPs were capable of passive accumulation in the same tumors 
initially classified as “EPR-positive” with the larger NPs. This is suggesting that the access and eventual positive 
accumulation of NPs is governed by the characteristics of the tumor itself. Indeed, interstitial blood pressure, vas-
cular architecture, permeability, and diffusion coefficients are defining a threshold authorizing or not the access 
to the tumor. This inter-tumor variation represents a major problem that can occur in patients and prevent access 
of the drugs to some tumors or metastasis28. To a certain extent, the physico-chemical parameters of the injected 
NPs play minor roles at this level (at least for those NPs that are already acceptable for intravenous injection). It 
seems particularly important to develop methods, including imaging, to anticipate a possible passive accumula-
tion13. Recently, a study demonstrated that the level of tumor vascularization, correlated with the EPR-mediated 
tumor accumulation of polymeric drug carrier, can be evaluated by contrast-enhanced functional ultrasound 
imaging29.
In this study, we used DCE-MRI (after injection of Gd-DOTA) and VSI-MRI (after injection of USPIOs), 
which can provide quantitative parameters of the tumor microenvironment in addition to tumor-specific vascular 
parameters abnormalities in preclinical cancer models15–17.
No direct correlation was found between the passive accumulation and the number and size of blood vessels, 
their permeability, quantity of blood or water diffusion coefficient. However, we established that the combination 
of “permeability” and “blood volume fraction” parameters enabled the prediction of whether the tested fluores-
cent NPs will accumulate or not in the different preclinical tumors. Importantly, this is not a prediction of the 
level of accumulation of the NPs, since this is definitely depending also on the NP’s pharmacokinetic properties, 
but rather on an ON/OFF type of response that is mainly related to the tumor characteristics.
Clinical studies also demonstrated the interest of DCE-MRI to differentiate between benign and malignant 
tumors30, assess the aggressiveness of tumors31,32 or predict the response to conventional chemotherapy33,34.
This approach may have a major impact on clinical practice. Indeed, these methods need to be validated in an 
appropriate cohort of patients to establish the optimal parameters to ensure the maximum distribution and reten-
tion in humans, which could differ from those required in animal models. Then a similar “classification scheme” 
could be determined in order to classify a given tumor as either “responsive” or “not-responsive”. A positive 
ranking suggests that nanomedicines will reach this particular tumor, whereas a negative one alerts the clinician 
to the possibility that the treatment may fail as a result of poor accessibility. Additionally, different strategies could 
be applied to augment the tumor responsiveness and overcome the heterogeneity of the EPR effect within tumor 
tissues35,36. These strategies could involve vascular-modulating agents such as angiotensin-II which induce hyper-
tension37, angiotensin II-converting enzyme (ACE) inhibitors which enhance bradykinin levels and nitric oxide 
production38, nitric oxide-realizing agents39,40, and hyperthermia41. These treatments can enhance the blood flow 
and vascular permeability in tumors or open occluded blood vessels42.
Conclusion
The present approach might be very useful in optimized and adaptive medicine based on the selection of patients 
using imaging, particularly MRI, for improved nanomedicine-based treatments.
Methods
Cell lines and culture conditions. The HUH-7 cell line, a well-differentiated cell line from a human dif-
ferentiated hepatocellular carcinoma43 (kindly provided by M. Ozturk (INSERM U823)), was cultured in DMEM 
plus 10% FBS (fetal bovine serum; Invitrogen, Cergy-Pontoise, France). IGROV1 human ovarian adenocarci-
noma cells44 (kindly provided by L. Poulain (Centre de Lutte contre le Cancer François Baclesse, Caen, France)) 
Figure 7. Passive accumulation of ultrasmall nanoparticles (USRPs) in three different subcutaneous 
tumors after intravenous injection. The USRPs were intravenously injected into subcutaneous tumor-bearing 
mice (n = 4/group). 2D-fluorescence imaging was performed before and 1.5 hours, 3 hours, 5 hours and 
24 hours after the injection of USRPs. Tumor and skin fluorescence signals were semi-quantified on whole-body 
images. The results are presented as the mean ± SD.
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were cultured in RPMI 1640 medium supplemented with 10% FBS and 1% glutamine. U87MG human primary 
glioblastoma cells (ATCC® HTB14™) were cultured in DMEM plus 10% FBS supplemented with non-essen-
tial amino acids. HT29 human colorectal adenocarcinoma cells (ATCC® HTB-38™) were cultured in McCoy’s 
medium supplemented with 10% FBS. Finally, TS/a-pc mouse mammary carcinoma cells45 were cultured in 
RPMI 1640 supplemented with 1% glutamine and 10% FBS. HEK293(β 3), stable transfectants of the human 
embryonic kidney cell line (kindly provided by J.-F. Gourvest, Aventis, France) were cultured in DMEM plus 10% 
FBS supplemented with 700 μ g/ml Geneticin (G418 sulfate; Gibco, Paisley, UK). Of note, the original HEK293 
cell line was obtained by the transformation of cultures of normal human embryonic kidney cells, and is not 
derived from a tumor. However, these cells form tumors when injected into nude mice. All of the cell lines were 
cultured at 37 °C in humidified 95% air/5% CO2 atmosphere.
Lipid nanoparticles preparation. The lipidic nanocapsules (LNCs) and the lipidic nanoemulsions 
(LNEs) were prepared as described in Hirsjärvi et al.26. The two types of nanoparticles were loaded with the DiD 
(1,1′-dioctadecyl-3,3,3′,3′-tetramethylindodicarbocyanine perchlorate) near infrared fluorescent dye (Invitrogen, 
Cergy-Pontoise, France). The final local dye concentration in the nanocarriers was approximately 4.4 mM. The 
nanoparticles have a diameter of 50 ± 1 nm, and a PolyDispersity Index of 0.03 and 0.19 for LNCs and LNEs, 
respectively. The complete description of LNCs and LNEs characteristics and in vivo biodistribution are provided 
in Supplementary Fig. 3 A,B.
Ultrasmall Nanoparticles. Ultrasmall rigid platforms (USRPs) were prepared as described previ-
ously21. They are composed of a polysiloxane network covalently grafted by gadolinium chelates [1,4,7,10-tetr
aazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-Gd]. They have a hydrodynamic diameter of 4.1 ± 1.0 nm 
and a zeta potential of − 0.2 mV at pH = 7.4. An average of one cyanine 5.5 molecule was grafted for every 550 
atoms of gadolinium. The description of USRPs characteristics and in vivo biodistribution are provided in 
Supplementary Fig. 3C.
Animal studies. Animal studies were performed in strict accordance with French Ministry of Agriculture 
regulations and were conducted with protocols approved by both the Ethical Committee of Grenoble and the 
Grenoble Institute of Neurosciences Ethical Committee.
In vivo experiments. Tumor-bearing mice were anesthetized using 4% isoflurane for induction and then at 
2% isoflurane to maintain the respiratory rate between 50 and 70 breaths/min.
A catheter filled with saline was inserted into the mouse tail vein to enable the injection of a contrast agent 
comprising the following: 100 μ l of LNC one hour before the beginning of the MRI studies, USPIO (P904; 
250 μ mol/kg, Guerbet, SA Aulnay-sous-Bois, France; apparent diameter of 25–30 nm; plasma half-life of approx-
imately 62 min) and Gd-DOTA (200 μ mol/kg; Dotarem®, Guerbet, France; apparent diameter of 1 nm, plasma 
half-life of approximately 26 min). Injections were always delivered manually and by the same investigator.
MRI was performed on a 4.7 T scanner (Biospec 47/40 USR AV III, Bruker, Germany – Grenoble MRI facility 
IRMaGE) equipped with a 12-cm inner diameter actively shielded gradient insert (640 mT/m in 120 μ s). Actively 
decoupled volume and surface coils were used for excitation and reception, respectively (Bruker, Germany). 
Animals were placed in the prone position. All the images were acquired in the coronal orientation.
MRI sequences were composed of the following views: I) An anatomical view (T2-weighted) RARE-T2 MRI 
(TR = 4 s, TE = 33 ms, 1-mm-thick slices, matrix = 196 × 196). This sequence was merely used for tumor locali-
zation; II) Diffusion-weighted, spin-echo, single shot, EPI-64 (EPI Diff; TR = 5 s, TE = 43 ms, 1-mm thick slices, 
matrix = 128 × 128). This sequence was applied four times: once without diffusion weighting and three times 
with diffusion weighting (b = 800 s.mm−1) in three orthogonal directions; III) Combined multi gradient-echo 
and spin-echo conventional MRI (MGESE; TR = 3 s, sixteen echoes evenly spaced gradient-echoes (GE) = 3 to 
83.1 ms, 1-mm-thick slices; matrix = 128 × 128). Immediately following this sequence, USPIOs were injected in 
5 s; IV) A repetition of step III following a delay of 20 s; V) Combined gradient-echo and spin-echo, single shot, 
EPI (EPI GESE; TR = 710 ms, TE = 5.21 ms, 1-mm-thick slices, matrix = 128 × 128). This MRI sequence was 
applied repeatedly during 20 min (1 image/15 seconds). The bolus of 20 μ l Gd-DOTA was injected 1 min after the 
beginning of this sequence over 2 s (flush of 70 μ l of saline solution) (Fig. 2).
Data processing. Data were processed in a MATLAB environment (v7.6; The MathWorks Inc., Natick, MA, 
USA). Regions of interest (ROIs) were manually slice-wise (1 mm thick) delineated for each mouse. The tumor 
and muscle ROIs were considered for each slide.
The tumor volume, water diffusion coefficient, blood volume fraction, vessel diameter, permeability and VSI 
were obtained for each slice. The results are expressed as the means of all the tumor slices for each mouse.
Image J® software was used for images processing (grayscale).
2D-FRI imaging. Tumor-bearing mice were intravenously injected either with DiD-loaded LNCs 
(100 μ l, [LNC] = 55 mg/ml)), DiD-loaded LNEs (200 μ l, [LNE] = 50 mg/ml) or cyanine5.5-USRPs (200 μ l, 
[Gd3+] = 10 mmol/L). Anesthetized mice were restrained in a prone position after induction and were illu-
minated by 660-nm light emitting diodes equipped with interference filters. Fluorescence reflectance images 
(FRI) were acquired over a period of 50 ms (for isolated organs) or 100 ms (for in vivo imaging), at different 
time points before and after injection of the NPs, with a back-thinned cooled charge-coupled device (CCD) 
camera (ORCAII-BT-512G, Hamamatsu Photonics, Massy, France) and a colored-glass RG9 high-pass filter 
(MellesGriot, Voisins le Bretonneux, France) to cut-off all excitation light. Semi-quantitative data were obtained 
from the fluorescence images of isolated organs by drawing regions of interest on the area to be quantified. The 
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results are expressed as photons/pixel/50 ms. Quantification and analysis of photons recorded on the images were 
carried out using the WASABI image software (Hamamatsu Photonics).
Immunohistochemical labeling. Tumor slices were placed at room temperature, fixed in acetone for 
10 min and washed twice in TBS with 0.1% Tween 20 (TBS/T). Endogenous peroxidases were blocked with 1% 
H2O2/methanol, and slices were rinsed in distilled water and TBS/T for 5 min. Tumor sections were blocked with 
2% rabbit serum diluted in TBS for 20 min and were rinsed for 5 min in TBS/T. CD31 was labeled with the rat 
anti-CD31 antibody for 1 hour (#550274 at 1/500; BD Biosciences, Pont de Claix, France) and the rabbit anti-rat 
antibody for 1 hour (#7077 at 1/750; Cell signaling Technology, Danvers, MA, USA). The labeling was detected 
with DAB for 5 min (#K3467; Dako, San Antonio, TX, USA) and rinsed with water for 5 min. Cell nuclei were 
stained with Gill’s hematoxylin for 2–3 s and washed with water 5 for min. Samples were dehydrated with 2 baths 
of 100% ethanol and one with xylene before the addition of mounting medium (M-GLAS, #1.03973.001; Merck 
Millipore, Fontenay sous bois, France). Images were taken using the Olympus BX-41 microscope with a 10× 
objective.
The evaluation of blood vessel number and diameter by CD31-quantification was performed on four fields of 
view for each tumor using Metamorph software.
Statistics. The predictive equation, its different parameters and its cross validation were determined using a 
stepwise method in SAS® software (SAS® Institute, North Carolina, USA).
The predictability of the “classification scheme” was evaluated by a Fischer test. A Wilcoxon test was applied to 
compare the vessel diameters evaluated by MRI and IHC in tumor sections.
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